Circulating miR-122 and miR-200a as biomarkers for fatal liver disease in ART-treated, HIV-1-infected individuals

[1]  Alissa M. Weaver,et al.  KRAS-MEK Signaling Controls Ago2 Sorting into Exosomes , 2016, Cell reports.

[2]  K. Chayama,et al.  MicroRNAs as Biomarkers for Liver Disease and Hepatocellular Carcinoma , 2016, International journal of molecular sciences.

[3]  Yu-feng Yuan,et al.  IL-6 Plays a Crucial Role in HBV Infection , 2015, Journal of clinical and translational hepatology.

[4]  M. Johnson,et al.  Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study , 2015, PloS one.

[5]  Mei-qi Zhang,et al.  MicroRNA-122 affects cell aggressiveness and apoptosis by targeting PKM2 in human hepatocellular carcinoma. , 2015, Oncology reports.

[6]  R. Metpally,et al.  microRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[7]  Xiaojian Zhao,et al.  MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer , 2015, Cytogenetic and Genome Research.

[8]  Ja Hyun Koo,et al.  Gα12 overexpressed in hepatocellular carcinoma reduces microRNA-122 expression via HNF4α inactivation, which causes c-Met induction , 2015, Oncotarget.

[9]  W. Lu,et al.  RETRACTED ARTICLE: p38/p53/miR-200a-3p feedback loop promotes oxidative stress-mediated liver cell death , 2015, Cell cycle.

[10]  S. Pfeffer,et al.  miR-122--a key factor and therapeutic target in liver disease. , 2015, Journal of hepatology.

[11]  Weilin Wang,et al.  miR-200a suppresses cell growth and migration by targeting MACC1 and predicts prognosis in hepatocellular carcinoma. , 2015, Oncology reports.

[12]  C. Strassburg,et al.  Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients , 2015, Hepatology.

[13]  A. Wree,et al.  Circulating Extracellular Vesicles with Specific Proteome and Liver MicroRNAs Are Potential Biomarkers for Liver Injury in Experimental Fatty Liver Disease , 2014, PloS one.

[14]  C. Shi,et al.  Aberrant Hepatic MicroRNA Expression in Nonalcoholic Fatty Liver Disease , 2014, Cellular Physiology and Biochemistry.

[15]  Yue Xu,et al.  MiR200-upregulated Vasohibin 2 promotes the malignant transformation of tumors by inducing epithelial-mesenchymal transition in hepatocellular carcinoma , 2014, Cell Communication and Signaling.

[16]  K. Kodys,et al.  Exosomes from Hepatitis C Infected Patients Transmit HCV Infection and Contain Replication Competent Viral RNA in Complex with Ago2-miR122-HSP90 , 2014, PLoS pathogens.

[17]  M. Caligiuri,et al.  Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. , 2012, The Journal of clinical investigation.

[18]  Xiuming Zhu,et al.  MicroRNA‐122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β‐catenin pathway , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[19]  X. Chen,et al.  Horizontal transfer of microRNAs: molecular mechanisms and clinical applications , 2012, Protein & Cell.

[20]  D. Boulware,et al.  Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. , 2011, The Journal of infectious diseases.

[21]  B. Burwinkel,et al.  Characterization of extracellular circulating microRNA , 2011, Nucleic acids research.

[22]  E. Kroh,et al.  Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma , 2011, Proceedings of the National Academy of Sciences.

[23]  Aybar C. Acar,et al.  mESAdb: microRNA Expression and Sequence Analysis Database , 2010, Nucleic Acids Res..

[24]  A. Mocroft,et al.  Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe , 2010, Journal of acquired immune deficiency syndromes.

[25]  B. Grinsztejn,et al.  Analysis of serious non‐AIDS events among HIV‐infected adults at Latin American sites , 2010, HIV medicine.

[26]  Asaf Levy,et al.  Discovery of microRNAs and other small RNAs in solid tumors , 2010, Nucleic acids research.

[27]  A. Mocroft,et al.  Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV , 2010, AIDS.

[28]  H. Lane,et al.  Interleukin-2 therapy in patients with HIV infection. , 2009, The New England journal of medicine.

[29]  S. Thorgeirsson,et al.  Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties , 2009, Oncogene.

[30]  Lianbo Yu,et al.  Detection of microRNA Expression in Human Peripheral Blood Microvesicles , 2008, PloS one.

[31]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[32]  R. Ach,et al.  Measuring microRNAs: Comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods , 2008, BMC biotechnology.

[33]  R. Davey,et al.  Determination of the Underlying Cause of Death in Three Multicenter International HIV Clinical Trials , 2008, HIV clinical trials.

[34]  L. Harrison,et al.  Increase in Non-AIDS Related Conditions as Causes of Death among HIV-Infected Individuals in the HAART Era in Brazil , 2008, PloS one.

[35]  D. Douek,et al.  Validation of RNA-based molecular clonotype analysis for virus-specific CD8+ T-cells in formaldehyde-fixed specimens isolated from peripheral blood. , 2007, Journal of immunological methods.

[36]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[37]  Melissa R Pfeiffer,et al.  Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City , 2006, Annals of Internal Medicine.

[38]  Kholoud Porter,et al.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.

[39]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[40]  M. Manns,et al.  The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. , 2005, The Journal of clinical investigation.

[41]  N. Kaplowitz,et al.  Serum alanine aminotransferase in skeletal muscle diseases , 2005, Hepatology.

[42]  C. Sander,et al.  miR-122, a Mammalian Liver-Specific microRNA, is Processed from hcr mRNA and MayDownregulate the High Affinity Cationic Amino Acid Transporter CAT-1 , 2004, RNA biology.

[43]  M. Burns,et al.  Case-Control Study , 2020, Definitions.

[44]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[45]  Thomas Pogge,et al.  From New York City , 2003, Science.

[46]  I. Ariyama,et al.  [Therapy of patients with HIV infection]. , 2001, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[47]  G. Ciliberto,et al.  Interleukin-6 Protects against Fas-mediated Death by Establishing a Critical Level of Anti-apoptotic Hepatic Proteins FLIP, Bcl-2, and Bcl-xL* , 2001, The Journal of Biological Chemistry.

[48]  H. Asakura,et al.  Ehanced expression of interleukin-6 in chronic hepatitis C , 1999 .

[49]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[50]  P. Clavien,et al.  Interleukin‐6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent , 1997, Hepatology.

[51]  S. Ikehara,et al.  Effect of human recombinant interleukin-6 on the proliferation of mouse hepatocytes in the primary culture. , 1990, Immunobiology.

[52]  Z. Du,et al.  Profiles of differential expression of circulating microRNAs in hepatitis B virus-positive small hepatocellular carcinoma. , 2015, Cancer biomarkers : section A of Disease markers.

[53]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[54]  小柳 佳成.  Enhanced expression of interleukin-6 in chronic hepatitis C , 2002 .

[55]  H. Asakura,et al.  Enhanced expression of interleukin-6 in chronic hepatitis C. , 1999, Liver.